Table 1.
Characteristics of TMD subjects
| Subject | Age (years) | Gender | Duration of pain (years) | Site | Pain intensity week before scanning (10 cm VAS) | Pain intensity before scan (10 cm VAS) | Analgesic medication |
|---|---|---|---|---|---|---|---|
| 151 | 38 | F | 6 | Right | 1.8 | 4.7 | Paracetamol |
| 201 | 59 | M | 20 | Bilateral | 5.9 | 6.0 | Amitriptyline hydrochloride |
| 203 | 59 | F | 30 | Bilateral | 7.9 | 7.6 | Venlafaxine, co-codamol |
| 206 | 53 | F | 3 | Bilateral | 2.5 | 3.1 | None |
| 228 | 47 | M | 20 | Bilateral | 2.9 | 2.7 | Paracetamol (PRN) |
| 253 | 42 | F | 3 | Bilateral | 0.2 | 0 | None |
| 256 | 70 | F | 11 | Bilateral | 0.7 | 4.6 | Aspirin |
| 259 | 62 | F | 5 | Bilateral | 5.4 | 3.9 | Diazepam, paracetamol |
| 267 | 45 | F | 2 | Bilateral | 1.5 | 1.1 | None |
| 268 | 37 | M | 6 | Bilateral | 7.3 | 7.0 | Botox |
| 275 | 41 | F | 4 | Right | 1.4 | 0.5 | None |
| 290 | 50 | F | 46 | Bilateral | 4.3 | 6.5 | Diclofenac |
| 294 | 45 | F | 5.5 | Bilateral | 4.1 | 7.3 | Oxycodone (PRN), paracetamol, co-codamol (PRN), doxylamine succinate, and codeine |
| 295 | 33 | F | 15 | Right | 5.9 | 5.5 | Doxylamine succinate and codeine (PRN) |
| 300 | 28 | M | 1.5 | Bilateral | 5.8 | 6.7 | Ibuprofen (PRN) |
| 301 | 24 | F | 7 | Bilateral | 5.5 | 5.9 | Amitriptyline hydrochloride, co-codamol, and sumatriptan |
| 304 | 66 | F | 5 | Bilateral | 3.1 | 1.1 | None |
| 313 | 50 | F | 3 | Bilateral | 2.7 | 2.0 | None |
| 314 | 37 | F | 4 | Bilateral | 2.2 | 5.5 | Ibuprofen (PRN) |
| 317 | 30 | F | 2 | Bilateral | 3.5 | 1.7 | Ibuprofen and paracetamol |
| Mean ± SEM | 46 ± 2.9 | 11.5 ± 3.4 | 3.7 ± 0.5 | 4.2 ± 0.5 |
All TMD patients fulfilled the criteria for TMD according to the Research Diagnostic Criteria for TMD (Dworkin and LeResche, 1992). PRN, Pro re nata (“as needed”); F, female; M, male.